EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics

Ashna A Kumar iD, Kara L Vine iD, Marie Ranson

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Ashna A Kumar und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia. Hauptthemen laut MEDLINE: Receptors, Urokinase Plasminogen Activator, Tumor Microenvironment, Urokinase-Type Plasminogen Activator. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 161 Literaturangaben. Gefördert von: Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aberrant proteolytic landscape of the tumor microenvironment is a key contributor of cancer progression. Overexpression of urokinase plasminogen activator (uPA) and/or its associated cell-surface receptor (uPAR) in tumor versus normal tissue is significantly associated with worse clinicopathological features and poorer patient survival across multiple cancer types. This is linked to mechanisms that facilitate tumor cell invasion and migration, via direct and downstream activation of various proteolytic processes that degrade the extracellular matrix─ultimately leading to metastasis. Targeting uPA has thus long been considered an attractive anticancer strategy. However, poor bioavailability of several uPA-selective small-molecule inhibitors has limited early clinical progress. Nanodelivery systems have emerged as an exciting method to enhance the pharmacokinetic (PK) profile of existing chemotherapeutics, allowing increased circulation time, improved bioavailability, and targeted delivery to tumor tissue. Combining uPA inhibitors with nanoparticle-based delivery systems thus offers a remarkable opportunity to overcome existing PK challenges associated with conventional uPA inhibitors, while leveraging potent candidates into novel targeted nanotherapeutics for an improved anticancer response in uPA positive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Urokinase Plasminogen ActivatorTumor MicroenvironmentUrokinase-Type Plasminogen ActivatorHumansNeoplasm Invasiveness

Stichwörter der Autor:innen

Cancer TherapyDrug DeliveryMetastasisNanomedicineSerine ProteaseTumorUrokinase Plasminogen Activator

Substanzen

Receptors, Urokinase Plasminogen ActivatorUrokinase-Type Plasminogen Activator

Autor:innen und Institutionen

  • School of Chemistry and Molecular Biosciences, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW 2522, Australia.

ORCID-Profile: Ashna A Kumar, Kara L Vine

Förderung

  • Australian Government

Zitieren

APA

Kumar, A. A., Vine, K. L., & Ranson, M. (2023). Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00055

Vancouver

Kumar AA, Vine KL, Ranson M. Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00055

BibTeX
@article{Kumar2023,
  author = {Kumar, Ashna A and Vine, Kara L and Ranson, Marie},
  title = {Recent Advances in Targeting the Urokinase Plasminogen Activator with Nanotherapeutics},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00055}
}
Kostenlos starten →